Hide metadata

dc.date.accessioned2023-03-07T17:42:00Z
dc.date.available2023-03-07T17:42:00Z
dc.date.created2022-10-19T11:09:02Z
dc.date.issued2022
dc.identifier.citationSilvennoinen, Katri Gawel, Kinga Aurelia Tsortouktzidis, Despina Pitsch, Julika Alhusaini, Saud van Loo, Karen M. J. Picardo, Richard Michalak, Zuzanna Pagni, Susanna Martins Custodio, Helena Mills, James Whelan, Christopher D. de Zubicaray, Greig I. McMahon, Katie L. van der Ent, Wietske Kirstein-Smardzewska, Karolina Joanna Tiraboschi, Ettore Mudge, Jonathan M. Frankish, Adam Thom, Maria Wright, Margaret J. Thompson, Paul M. Schoch, Susanne Becker, Albert J. Esguerra, Camila Sisodiya, Sanjay M. . SCN1A overexpression, associated with a genomic region marked by a risk variant for a common epilepsy, raises seizure susceptibility. Acta Neuropathologica. 2022, 144(1), 107-127
dc.identifier.urihttp://hdl.handle.net/10852/100971
dc.description.abstractAbstract Mesial temporal lobe epilepsy with hippocampal sclerosis and a history of febrile seizures is associated with common variation at rs7587026, located in the promoter region of SCN1A. We sought to explore possible underlying mechanisms. SCN1A expression was analysed in hippocampal biopsy specimens of individuals with mesial temporal lobe epilepsy with hippocampal sclerosis who underwent surgical treatment, and hippocampal neuronal cell loss was quantitatively assessed using immunohistochemistry. In healthy individuals, hippocampal volume was measured using MRI. Analyses were performed stratified by rs7587026 type. To study the functional consequences of increased SCN1A expression, we generated, using transposon-mediated bacterial artificial chromosome transgenesis, a zebrafish line expressing exogenous scn1a , and performed EEG analysis on larval optic tecta at 4 day post-fertilization. Finally, we used an in vitro promoter analysis to study whether the genetic motif containing rs7587026 influences promoter activity. Hippocampal SCN1A expression differed by rs7587026 genotype (Kruskal–Wallis test P  = 0.004). Individuals homozygous for the minor allele showed significantly increased expression compared to those homozygous for the major allele (Dunn’s test P  = 0.003), and to heterozygotes (Dunn’s test P  = 0.035). No statistically significant differences in hippocampal neuronal cell loss were observed between the three genotypes. Among 597 healthy participants, individuals homozygous for the minor allele at rs7587026 displayed significantly reduced mean hippocampal volume compared to major allele homozygotes (Cohen’s D  = − 0.28, P  = 0.02), and to heterozygotes (Cohen’s D  = − 0.36, P  = 0.009). Compared to wild type, scn1lab -overexpressing zebrafish larvae exhibited more frequent spontaneous seizures [one-way ANOVA F (4,54) = 6.95 ( P  < 0.001)]. The number of EEG discharges correlated with the level of scn1lab overexpression [one-way ANOVA F (4,15) = 10.75 ( P  < 0.001]. Finally, we showed that a 50 bp promoter motif containing rs7587026 exerts a strong regulatory role on SCN1A expression, though we could not directly link this to rs7587026 itself. Our results develop the mechanistic link between rs7587026 and mesial temporal lobe epilepsy with hippocampal sclerosis and a history of febrile seizures. Furthermore, we propose that quantitative precision may be important when increasing SCN1A expression in current strategies aiming to treat seizures in conditions involving SCN1A haploinsufficiency, such as Dravet syndrome.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleSCN1A overexpression, associated with a genomic region marked by a risk variant for a common epilepsy, raises seizure susceptibility
dc.title.alternativeENEngelskEnglishSCN1A overexpression, associated with a genomic region marked by a risk variant for a common epilepsy, raises seizure susceptibility
dc.typeJournal article
dc.creator.authorSilvennoinen, Katri
dc.creator.authorGawel, Kinga Aurelia
dc.creator.authorTsortouktzidis, Despina
dc.creator.authorPitsch, Julika
dc.creator.authorAlhusaini, Saud
dc.creator.authorvan Loo, Karen M. J.
dc.creator.authorPicardo, Richard
dc.creator.authorMichalak, Zuzanna
dc.creator.authorPagni, Susanna
dc.creator.authorMartins Custodio, Helena
dc.creator.authorMills, James
dc.creator.authorWhelan, Christopher D.
dc.creator.authorde Zubicaray, Greig I.
dc.creator.authorMcMahon, Katie L.
dc.creator.authorvan der Ent, Wietske
dc.creator.authorKirstein-Smardzewska, Karolina Joanna
dc.creator.authorTiraboschi, Ettore
dc.creator.authorMudge, Jonathan M.
dc.creator.authorFrankish, Adam
dc.creator.authorThom, Maria
dc.creator.authorWright, Margaret J.
dc.creator.authorThompson, Paul M.
dc.creator.authorSchoch, Susanne
dc.creator.authorBecker, Albert J.
dc.creator.authorEsguerra, Camila
dc.creator.authorSisodiya, Sanjay M.
cristin.unitcode185,57,10,0
cristin.unitnameNorsk Senter for Molekylærmedisin (NCMM) Admin og kjernefasiliteter
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2062691
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Acta Neuropathologica&rft.volume=144&rft.spage=107&rft.date=2022
dc.identifier.jtitleActa Neuropathologica
dc.identifier.volume144
dc.identifier.issue1
dc.identifier.startpage107
dc.identifier.endpage127
dc.identifier.doihttps://doi.org/10.1007/s00401-022-02429-0
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn0001-6322
dc.type.versionPublishedVersion
dc.relation.projectNFR/187615


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International